Nutriband Inc. - Common Stock (NTRB)
6.8500
-0.3200 (-4.46%)
NASDAQ · Last Trade: Aug 12th, 2:08 AM EDT
Detailed Quote
| Previous Close | 7.170 |
|---|---|
| Open | 6.930 |
| Bid | 6.500 |
| Ask | 6.730 |
| Day's Range | 6.660 - 7.190 |
| 52 Week Range | 3.722 - 11.78 |
| Volume | 106,118 |
| Market Cap | 43.54M |
| PE Ratio (TTM) | -7.611 |
| EPS (TTM) | -0.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 186,566 |
Chart
About Nutriband Inc. - Common Stock (NTRB)
Nutriband Inc is a biotechnology company focused on the development and commercialization of innovative transdermal drug delivery systems and other advanced technologies for the pharmaceutical and healthcare industries. By leveraging cutting-edge research and proprietary platforms, the company aims to enhance the efficacy and safety of medications, providing solutions that improve patient compliance and therapeutic outcomes. Their product pipeline includes a range of applications, from pain management to the treatment of various medical conditions, reflecting their commitment to advancing healthcare through technology. Read More
News & Press Releases
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Steps Aside Temporarily to Run for Irish Presidency
Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will step aside for three months to pursue candidacy in the Irish Presidential election, with nomination hearings and voting taking place in September and October. Co-Founder and Chairman Serguei Melnik, a corporate strategy expert with over 20 years in capital markets, will assume CEO duties during this period, guiding the company toward its 2026 NDA filing target. Sheridan emphasized confidence in the leadership team, noting continued progress on AVERSA Fentanyl, which the FDA recently granted a meeting request for. AVERSA Fentanyl is positioned to be the first abuse-deterrent opioid patch, designed to deter misuse and accidental exposure, with potential peak U.S. sales estimated at $80 million to $200 million. The technology is protected by patents in 46 countries, with plans to expand availability to major global medical markets.
Via Investor Brand Network · August 11, 2025
Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election.
By Nutriband Inc. · Via GlobeNewswire · August 11, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the U.S. Food and Drug Administration has granted a Type C Meeting on Sept. 18, 2025, to review Chemistry, Manufacturing, and Controls plans for its lead product, AVERSA(TM) Fentanyl. Developed in partnership with Kindeva, the patch integrates Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch to help prevent abuse, diversion, misuse, and accidental exposure while maintaining access for patients in need. Positioned to be the world’s first abuse-deterrent opioid patch, AVERSA Fentanyl targets peak annual U.S. sales potential of $80 million to $200 million, with future global market expansion planned. The technology is protected by patents in 46 countries.
Via Investor Brand Network · August 8, 2025
Via Benzinga · August 8, 2025
FDA grants meeting for AVERSA™ FENTANYL (abuse deterrent transdermal system) to provide feedback on the Chemistry, Manufacturing, and Controls plans for the product through commercialization.
By Nutriband Inc. · Via GlobeNewswire · August 8, 2025
Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech
Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to deliver medications that require careful balancing of patient access with strong mitigation against misuse.
Via Investor Brand Network · August 6, 2025
Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone
Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug’s safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable risks reach patients. Recognizing the immense value this milestone represents, Nutriband (NASDAQ: NTRB) recently underscored its commitment to this pathway by announcing a 25% preferred stock dividend as the company targets filing for FDA approval for its lead product, AVERSA(TM) Fentanyl ( https://ibn.fm/8FRUA ).
Via Investor Brand Network · August 5, 2025
BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB): Innovation Meets Science Through Scalable Platform
Nutriband (NASDAQ: NTRB) is positioning at the forefront of abuse-deterrent drug delivery in advancing its flagship fentanyl patch and buprenorphine candidates. The company combines transdermal innovation with abuse-deterrent science to meet critical public health needs. According to Nurtiband, AVERSA Fentanyl, with the possibility to reach peak annual U.S. sales of $80 to $200 million, holds the potential to be the world’s first opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. In addition, Nutriband is advancing AVERSA Buprenorphine, which upon approval is projected to achieve peak U.S. sales between $70 and $130 million. Both candidates benefit from Nutriband’s scalable platform, and the technology is on track for global patent protection.
Via Investor Brand Network · July 25, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sets Key Dates for 25% Preferred Stock Dividend
Nutriband (NASDAQ: NTRB) is reminding shareholders of its upcoming 25% preferred stock dividend. Shareholders of record as of July 25, 2025, will receive one preferred share for every four common shares held, with the dividend payable on August 5. Each preferred share will be convertible to one common share upon FDA approval of Nutriband’s AVERSA Fentanyl product. Unconverted preferred shares will be eligible for annual cash dividends from company profits at the discretion of the board.
Via Investor Brand Network · July 18, 2025
ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend.
By Nutriband Inc. · Via GlobeNewswire · July 18, 2025
InvestorNewsBreaks – Rare Biotech Story: Nutriband Inc. (NASDAQ: NTRB) Founder Shares Vision in Smart Money Circle Podcast
Nutriband (NASDAQ: NTRB) was recently featured on the Smart Money Circle Show, where Serguei Melnik, NTRB’s founder and president, unveiled his no-nonsense approach to biotech entrepreneurship. Standing in stark contrast to the conventional playbook are his grounded tone and unwavering focus on long-term value. An article discussing this reads, “Unlike most early-stage biotech companies, Nutriband generates revenue today. The company operates a manufacturing facility in North Carolina that produces the Active Intelligence tape used by Reebok, among others. The company also recently launched a mosquito-repelling patch, now approved for sale in Costa Rica. Melnik and his team personally tested the product by trekking through the Talamanca Mountain range without a single mosquito bite in four days… Melnik isn’t just a president; he’s a founder with skin in the game… His grounded mindset, passion for innovation, and unwillingness to compromise on shareholder value position Nutriband as a rare biotech story, one led by integrity, resilience, and vision that is nearing some critical milestones that could serve as significant catalysts to corporate value.”
Via Investor Brand Network · July 11, 2025
Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis
The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe pain, their high abuse potential has led to a growing demand for smarter, safer delivery systems. As policymakers, healthcare providers, and regulators seek solutions that balance medical necessity with public safety, innovative technologies are emerging that could reshape how these powerful drugs are administered.
Via Investor Brand Network · July 3, 2025
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Declares 25% Preferred Stock Dividend Linked to AVERSA Fentanyl Approval
Nutriband (NASDAQ: NTRB) announced that its Board of Directors has approved a 25% preferred stock dividend, granting one preferred share for every four common shares held as of July 25, 2025, with distribution set for August 5. Each preferred share will convert to one common share upon FDA approval of the Company’s AVERSA Fentanyl product. If not converted, preferred shares will be eligible for annual cash dividends from company profits at the Board’s discretion. CEO Gareth Sheridan said the move reflects the Company’s commitment to shareholder value as it advances toward AVERSA commercialization.
Via Investor Brand Network · July 2, 2025
ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) announced today that its Board of Directors has approved and declared a 25% preferred stock dividend.
By Nutriband Inc. · Via GlobeNewswire · July 2, 2025
Investing in Innovation: Four Small-Caps Driving the Future of Pain Therapy (NTRB, COLL, ASRT, AQST)
The global transdermal patch market is quietly gaining ground. Valued at $7.8 billion in 2023, it is projected to reach nearly $10.95 billion by 2030. Within that, pain patches are leading the way, expected to grow from $4.8 billion in 2021 to $7.3 billion by 2031.
Via AB Newswire · July 2, 2025
Investing in Innovation: Four Small-Caps Driving the Future of Pain Therapy
Via News Direct · July 2, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Added to Four Russell Indexes in 2025 Reconstitution
Nutriband (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. CEO Gareth Sheridan called the inclusion a reflection of market recognition and momentum behind the company’s AVERSA pipeline, particularly AVERSA Fentanyl, which has potential peak annual U.S. sales between $80 million and $200 million. Russell indexes, maintained by FTSE Russell, benchmark approximately $10.6 trillion in assets and are widely used by investment managers and institutions.
Via Investor Brand Network · July 1, 2025
ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth Indexes, as part of the 2025 Russell indexes reconstitution.
By Nutriband Inc. · Via GlobeNewswire · July 1, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Price Target Raised to $15 Following AVERSA Fentanyl Manufacturing Milestone
Nutriband (NASDAQ: NTRB) has received a new $15 price target in an updated report from Robert LeBoyer, Senior Vice President and Equity Research Analyst, Biotechnology, at Noble Capital Markets, following the successful completion of commercial manufacturing and scale-up for AVERSA Fentanyl, its abuse-deterrent transdermal patch developed in partnership with Kindeva.
Via Investor Brand Network · June 23, 2025
Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation
The opioid crisis remains one of the most persistent public health emergencies in the U.S. While state and federal initiatives have helped curb some of the worst-case trajectories, more than 100,000 Americans still die each year from drug overdoses, a significant proportion linked to synthetic opioids like fentanyl. The crisis is evolving, not disappearing, and the pharmaceutical industry continues to grapple with the challenge of balancing patient access with the need for safety and deterrence.
Via Investor Brand Network · June 20, 2025
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the successful commercial manufacturing process scale-up of its lead product, Aversa Fentanyl, in collaboration with Kindeva, a global CDMO specializing in drug-device combinations. Aversa Fentanyl integrates Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch and is produced at Kindeva’s U.S.-based transdermal facility. The next step involves producing clinical supplies and submitting an Investigational New Drug application to begin a human abuse liability study. Nutriband projects Aversa Fentanyl, which aims to be the world’s first abuse-deterrent opioid patch, could achieve peak U.S. sales between $80 million and $200 million, with broader global market ambitions supported by its extensive international patent portfolio.
Via Investor Brand Network · June 18, 2025
Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patch. Nutriband is partnering with Kindeva to develop Aversa™ Fentanyl which combines Nutriband’s Aversa™ abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. Orlando, FL – June 18, 2025 – Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in […]
Via FinancialNewsMedia · June 18, 2025
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END
Via FinancialNewsMedia · June 18, 2025
PALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's estimated that replacing extended-release opioids with abuse-deterrent formulations could lead to significant cost savings and a reduction in abuse-related medical events. While specific revenue figures for the abuse-deterrent opioid market are not readily available, the potential impact on the broader opioid market is substantial. One such report from Roots Analysis, however, did project revenues, saying: “The abuse deterrent formulations market is estimated to grow from USD 25.7 million in 2024 to reach USD 39.8 million in 2025 and USD 54.8 million by 2030, representing a higher CAGR of 6.6% during the forecast period. Although the healthcare industry relies on patient to take medications responsibly, in 2017, close to 18 million individuals were reported to have misused prescription drugs, in the US. In fact, data from a National Survey on Drug Use and Health conducted in the same year, showed that an estimated 2 million Americans misused prescription pain relievers for the first time in the previous year. Moreover, the same study reported 1.5 million people abusing tranquilizers, over 1 million abusing prescription stimulants and more than 270,000 abusing sedatives, for the first time, in the same time period. Owing to a rapid onset of medicinal effect, which offers immediate relief (with high efficacy), opioids are still considered to be one of the most widely used pharmacological interventions for pain management. However, these drugs are known to induce a euphoric state upon consumption, often causing patients to abuse them; increased recreational use of opioids is known to lead to addiction. Moreover, over-prescription of such medicinal products, which promotes their misuse, is considered as one of the root causes of the opioid crisis (increasing number of deaths involving misuse and addiction to opioids), in the US. According to the Centers for Disease Control and Prevention (CDC), more than 72,000 overdose-related deaths were reported in 2017, of which close to 50,000 involved the use of an opioid.” Active healthcare/tech companies active in the markets include: Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), Pfizer Inc. (NYSE: PFE), Collegium Pharmaceutical, Inc. (NASDAQ: COLL), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Emergent BioSolutions Inc. (NYSE: EBS).
By FN Media Group LLC · Via GlobeNewswire · June 18, 2025